Nakstad: Dobbelt munnbind kan bli anbefalt i Norge aftenposten.no - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aftenposten.no Daily Mail and Mail on Sunday newspapers.
The Stolen Cells Of Henrietta Lacks
Microscope image of Henrietta Lacks (HeLa) cells undergoing division. CC BY SA 3.0 0 October 31, 2020 15:47 by Matthew Bird
Sarvenaz Hosseini
Would you want your cells to live on beyond your death without your consent? How would your children and grandchildren feel knowing bits of you are in labs all over the world without you or them having a say? Studied and examined. Your full genome posted in a journal for everyone to access, even though you have dozens of descendants who carry your genes.
Henrietta Lacks’ gravestone is inscribed with “Her immortal cells will continue to help mankind forever”. Born in 1920, Henrietta was a religious Black woman who liked to paint her nails and took pride in herself.
После закрытия телеканалов радикализация перейдет с диванов на улицы, – аналитик zikua.tv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zikua.tv Daily Mail and Mail on Sunday newspapers.
Credit: RedHill Biopharma
Opaganib targets a human cell component involved in viral replication and is therefore expected to be effective against emerging viral variants with mutations in the spike protein
Preliminary data from the non-powered U.S. Phase 2 study of opaganib demonstrated safety and positive efficacy data across key primary and secondary endpoints
TEL AVIV, Israel and RALEIGH, NC, January 29, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Share this article
Share this article
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib
[1] in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients. Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity. The positive and unanimous DSMB recommendation is a significant milestone in the progress of our development program for COVID-19 disease. Taken together with the positive results from the Phase 2 study, this unanimous DSMB recommendation to continue the global P